Business
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
Study documents 100 percent concordance between EsoGuard® test results and subsequent medical decision-making Timely results support recently proposed federal
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Study documents 100 percent concordance between EsoGuard® test results and subsequent medical decision-making\nTimely results support recently proposed federal legislation which seeks to fund guaranteed fire fighter access to early detection tests such as EsoGuard\nNEW YORK, Sept. 6, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( \"PAVmed\"), today announced it has released positive data from a retrospective analysis demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer in a large cohort of fire fighters.\n\n \n \n \n \n \n \n\n \nThe study documents 100 percent concordance between clinically directed EsoGuard test results and subsequent medical decision-making by the prescribing physician. It demonstrates that EsoGuard can efficiently test large populations at risk for esophageal precancer, allowing physicians to utilize EsoGuard results to appropriately triage those requiring confirmatory endoscopy in a manner broadly consistent with established, and recently updated, professional society guidelines. The manuscript, entitled Clinical Utility of EsoGuard® as a Triage Test for Endoscopy to Identify Barrett's Esophagus in Fire Fighters, has been posted on the leading health sciences preprint server, medRxiv, pending peer review and publication. The release of these data closely aligns with and strongly supports recently proposed federal legislation seeking to fund guaranteed firefighter access to early detection tests such as EsoGuard.\n\"The release of these results represents a very important milestone for Lucid. We can now, for the first time, demonstrate to payors that physicians are clinically utilizing EsoGuard to appropriately guide their referral of at-risk patients for confirmatory endoscopy, namely—that our diagnostic test has meaningful real-world clinical utility,\" said Natalie Carfora, Lucid's new Vice President, Market Access. \"Such clinical utility data, along with claims history, has been a key gating item for us to engage payors to secure in-network EsoGuard coverage. This retrospective analysis is the first of four clinical utility studies that we will be releasing as p...